<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">
    <meta name="apple-mobile-web-app-capable" content="yes">
    <title>ABIM Pulmonology Study Guide</title>
    <style>
        * { box-sizing: border-box; -webkit-tap-highlight-color: rgba(8, 145, 178, 0.2); }
        body { font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif; line-height: 1.6; color: #1e293b; max-width: 1200px; margin: 0 auto; padding: 20px; padding-bottom: 80px; background: linear-gradient(135deg, #ecfeff 0%, #f0f9ff 100%); min-height: 100vh; }
        h1 { color: #0891b2; border-bottom: 3px solid #0891b2; padding-bottom: 10px; font-size: 1.75rem; }
        h2 { color: #0e7490; border-bottom: 2px solid #a5f3fc; padding-bottom: 8px; margin-top: 0; font-size: 1.4rem; }
        h3 { color: #155e75; margin-top: 20px; font-size: 1.15rem; border-left: 4px solid #0891b2; padding-left: 12px; }
        h4 { color: #164e63; margin-top: 15px; font-size: 1rem; }
        .header-box { background: linear-gradient(135deg, #0891b2 0%, #06b6d4 50%, #22d3ee 100%); color: white; padding: 30px 24px; border-radius: 16px; margin-bottom: 24px; text-align: center; box-shadow: 0 4px 20px rgba(8, 145, 178, 0.3); }
        .header-box h1 { color: white; border: none; margin: 0; font-size: 1.9rem; }
        .header-box .subtitle { font-size: 1rem; opacity: 0.95; margin-top: 8px; }
        .header-box .build-tag { display: inline-block; background: rgba(255,255,255,0.2); padding: 4px 14px; border-radius: 20px; font-size: 0.85rem; margin-top: 12px; }
        .search-container { padding: 16px 20px; background: white; border-radius: 12px; margin-bottom: 20px; box-shadow: 0 2px 8px rgba(0,0,0,0.06); }
        .search-box { width: 100%; padding: 14px 20px; border: 2px solid #a5f3fc; border-radius: 25px; font-size: 1rem; outline: none; }
        .search-box:focus { border-color: #0891b2; box-shadow: 0 0 0 3px rgba(8, 145, 178, 0.15); }
        .nav-container { position: sticky; top: 0; z-index: 100; background: rgba(236, 254, 255, 0.95); backdrop-filter: blur(10px); padding: 12px 0; margin: 0 -20px 20px -20px; padding-left: 20px; padding-right: 20px; border-bottom: 1px solid #a5f3fc; }
        .nav-pills { display: flex; overflow-x: auto; gap: 8px; padding-bottom: 8px; -webkit-overflow-scrolling: touch; scrollbar-width: none; }
        .nav-pills::-webkit-scrollbar { display: none; }
        .nav-pill { flex-shrink: 0; padding: 10px 18px; background: white; color: #0e7490; text-decoration: none; border-radius: 22px; font-size: 0.9rem; font-weight: 500; border: 2px solid #a5f3fc; white-space: nowrap; }
        .nav-pill:hover, .nav-pill:active { background: #0891b2; color: white; border-color: #0891b2; }
        .section { background: white; margin-bottom: 20px; padding: 24px; border-radius: 12px; border-left: 5px solid #0891b2; box-shadow: 0 2px 8px rgba(0,0,0,0.06); }
        .section-header { cursor: pointer; display: flex; justify-content: space-between; align-items: center; }
        .section-header::after { content: '‚ñº'; font-size: 0.8rem; color: #0891b2; transition: transform 0.3s ease; }
        .section.collapsed .section-header::after { transform: rotate(-90deg); }
        .section.collapsed .section-content { display: none; }
        .section-content { margin-top: 16px; }
        table { width: 100%; border-collapse: collapse; margin: 16px 0; font-size: 0.9rem; }
        th, td { border: 1px solid #a5f3fc; padding: 12px; text-align: left; }
        th { background: linear-gradient(135deg, #0891b2 0%, #06b6d4 100%); color: white; font-weight: 600; }
        tr:nth-child(even) { background: #ecfeff; }
        tr:hover { background: #cffafe; }
        ul, ol { margin: 12px 0; padding-left: 24px; }
        li { margin: 8px 0; }
        .high-yield { background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%); border: 2px solid #f59e0b; border-radius: 10px; padding: 16px; margin: 16px 0; }
        .high-yield::before { content: "‚≠ê HIGH-YIELD: "; font-weight: 700; color: #d97706; }
        .clinical-pearl { background: linear-gradient(135deg, #dbeafe 0%, #e0f2fe 100%); border: 2px solid #3b82f6; border-radius: 10px; padding: 16px; margin: 16px 0; }
        .clinical-pearl::before { content: "üíé CLINICAL PEARL: "; font-weight: 700; color: #2563eb; }
        .danger-box { background: linear-gradient(135deg, #fee2e2 0%, #fecaca 100%); border: 2px solid #ef4444; border-radius: 10px; padding: 16px; margin: 16px 0; }
        .danger-box::before { content: "üö® DANGER: "; font-weight: 700; color: #dc2626; }
        .guideline-box { background: linear-gradient(135deg, #f3e8ff 0%, #ede9fe 100%); border: 2px solid #8b5cf6; border-radius: 10px; padding: 16px; margin: 16px 0; }
        .guideline-box::before { content: "üìã GUIDELINE: "; font-weight: 700; color: #7c3aed; }
        .mnemonic-box { background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%); border: 2px solid #10b981; border-radius: 10px; padding: 16px; margin: 16px 0; }
        .mnemonic-box::before { content: "üß† MNEMONIC: "; font-weight: 700; color: #059669; }
        .formula-box { background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); border: 2px solid #0284c7; border-radius: 10px; padding: 16px; margin: 16px 0; font-family: 'SF Mono', Monaco, monospace; }
        .formula-box::before { content: "üî¢ FORMULA: "; font-weight: 700; color: #0369a1; font-family: -apple-system, sans-serif; }
        .badge { display: inline-block; padding: 3px 10px; border-radius: 12px; font-size: 0.75rem; font-weight: 600; margin-left: 8px; }
        .badge-common { background: #dbeafe; color: #1d4ed8; }
        .badge-danger { background: #fee2e2; color: #dc2626; }
        .badge-boards { background: #fef3c7; color: #d97706; }
        .back-to-top { position: fixed; bottom: 30px; right: 30px; width: 56px; height: 56px; background: linear-gradient(135deg, #0891b2 0%, #06b6d4 100%); color: white; border: none; border-radius: 50%; font-size: 1.5rem; cursor: pointer; box-shadow: 0 4px 15px rgba(8, 145, 178, 0.4); display: none; align-items: center; justify-content: center; z-index: 1000; }
        .back-to-top.show { display: flex; }
        footer { background: linear-gradient(135deg, #0891b2 0%, #06b6d4 50%, #22d3ee 100%); color: white; padding: 30px 24px; border-radius: 16px; margin-top: 40px; text-align: center; }
        footer a { color: white; text-decoration: none; background: rgba(255,255,255,0.2); padding: 10px 20px; border-radius: 22px; margin: 6px; display: inline-block; font-size: 0.9rem; }
        footer a:hover { background: rgba(255,255,255,0.3); }
        @media (min-width: 768px) and (max-width: 1024px) { body { padding: 24px 28px; } .header-box { padding: 36px 30px; } .header-box h1 { font-size: 2.2rem; } .section { padding: 28px; } h2 { font-size: 1.5rem; } }
        @media (max-width: 767px) { .header-box h1 { font-size: 1.5rem; } .section { padding: 18px; } table { font-size: 0.8rem; } th, td { padding: 8px; } }
        @media (pointer: coarse) { .nav-pill, .section-header, button { min-height: 44px; } }
        @supports (padding: max(0px)) { body { padding-left: max(20px, env(safe-area-inset-left)); padding-right: max(20px, env(safe-area-inset-right)); padding-bottom: max(80px, env(safe-area-inset-bottom)); } }
    </style>
</head>
<body>

<div class="header-box">
    <h1>ü´Å ABIM Pulmonology Study Guide</h1>
    <div class="subtitle">High-Yield Board Review ‚Ä¢ ATS/GOLD/CHEST Guidelines</div>
    <div class="build-tag">BUILD #1 ‚Ä¢ 45 SECTIONS ‚Ä¢ DECEMBER 2025</div>
</div>

<div class="search-container">
    <input type="text" class="search-box" id="searchBox" placeholder="Search topics, conditions, medications..." autocomplete="off">
</div>

<nav class="nav-container">
    <div class="nav-pills">
        <a href="#obstructive" class="nav-pill">Obstructive</a>
        <a href="#restrictive" class="nav-pill">Restrictive</a>
        <a href="#ild" class="nav-pill">ILD</a>
        <a href="#infections" class="nav-pill">Infections</a>
        <a href="#vte" class="nav-pill">VTE</a>
        <a href="#pleural" class="nav-pill">Pleural</a>
        <a href="#cancer" class="nav-pill">Lung Cancer</a>
        <a href="#sleep" class="nav-pill">Sleep</a>
        <a href="#icu" class="nav-pill">Critical Care</a>
        <a href="#pfts" class="nav-pill">PFTs</a>
    </div>
</nav>

<!-- SECTION 1: ASTHMA -->
<div class="section" id="obstructive">
    <div class="section-header">
        <h2>1. Asthma <span class="badge badge-common">Very Common</span></h2>
    </div>
    <div class="section-content">
        <h3>Definition & Pathophysiology</h3>
        <ul>
            <li>Chronic airway inflammation with reversible airflow obstruction</li>
            <li>Bronchial hyperresponsiveness</li>
            <li>Key cells: Eosinophils, mast cells, Th2 lymphocytes</li>
        </ul>
        
        <h3>Diagnosis</h3>
        <ul>
            <li><strong>Spirometry:</strong> FEV1/FVC ratio <0.70 with <strong>‚â•12% AND ‚â•200 mL improvement post-bronchodilator</strong></li>
            <li><strong>Methacholine challenge:</strong> PC20 <4 mg/mL (positive if FEV1 drops ‚â•20%)</li>
            <li><strong>Peak flow variability:</strong> >20% diurnal variation</li>
            <li><strong>FeNO:</strong> >50 ppb suggests eosinophilic inflammation</li>
        </ul>
        
        <h3>GINA Classification (2023)</h3>
        <table>
            <tr><th>Severity</th><th>Daytime Symptoms</th><th>Night Symptoms</th><th>FEV1</th></tr>
            <tr><td><strong>Intermittent</strong></td><td>‚â§2 days/week</td><td>‚â§2√ó/month</td><td>>80%</td></tr>
            <tr><td><strong>Mild Persistent</strong></td><td>>2 days/week</td><td>3-4√ó/month</td><td>‚â•80%</td></tr>
            <tr><td><strong>Moderate Persistent</strong></td><td>Daily</td><td>>1√ó/week</td><td>60-80%</td></tr>
            <tr><td><strong>Severe Persistent</strong></td><td>Throughout day</td><td>Often nightly</td><td><60%</td></tr>
        </table>
        
        <h3>Treatment Stepwise Approach</h3>
        <table>
            <tr><th>Step</th><th>Controller</th><th>Reliever</th></tr>
            <tr><td>1</td><td>PRN low-dose ICS-formoterol</td><td>PRN ICS-formoterol</td></tr>
            <tr><td>2</td><td>Daily low-dose ICS OR PRN ICS-formoterol</td><td>PRN SABA or ICS-formoterol</td></tr>
            <tr><td>3</td><td>Low-dose ICS-LABA</td><td>PRN ICS-formoterol preferred</td></tr>
            <tr><td>4</td><td>Medium-dose ICS-LABA</td><td>PRN ICS-formoterol</td></tr>
            <tr><td>5</td><td>High-dose ICS-LABA + add-on (LAMA, biologic)</td><td>PRN ICS-formoterol</td></tr>
        </table>
        
        <div class="high-yield">
            GINA 2023: PRN ICS-formoterol (SMART therapy) now preferred over SABA-only as reliever at ALL steps. Reduces exacerbations.
        </div>
        
        <h3>Biologics for Severe Asthma</h3>
        <table>
            <tr><th>Drug</th><th>Target</th><th>Indication</th></tr>
            <tr><td><strong>Omalizumab</strong></td><td>IgE</td><td>Allergic asthma, elevated IgE</td></tr>
            <tr><td><strong>Mepolizumab, Benralizumab</strong></td><td>IL-5/IL-5R</td><td>Eosinophilic asthma (‚â•150-300)</td></tr>
            <tr><td><strong>Dupilumab</strong></td><td>IL-4/IL-13</td><td>Eosinophilic or FeNO ‚â•25</td></tr>
            <tr><td><strong>Tezepelumab</strong></td><td>TSLP</td><td>Severe asthma (any phenotype)</td></tr>
        </table>
    </div>
</div>

<!-- SECTION 2: ACUTE ASTHMA -->
<div class="section" id="acute-asthma">
    <div class="section-header">
        <h2>2. Acute Asthma Exacerbation <span class="badge badge-danger">Emergency</span></h2>
    </div>
    <div class="section-content">
        <h3>Severity Assessment</h3>
        <table>
            <tr><th>Feature</th><th>Mild-Moderate</th><th>Severe</th><th>Life-Threatening</th></tr>
            <tr><td>Talks in</td><td>Sentences</td><td>Words</td><td>Cannot speak</td></tr>
            <tr><td>RR</td><td>Increased</td><td>>30</td><td>Exhaustion</td></tr>
            <tr><td>HR</td><td>100-120</td><td>>120</td><td>Bradycardia</td></tr>
            <tr><td>SpO2</td><td>90-95%</td><td><90%</td><td><90%</td></tr>
            <tr><td>PEF</td><td>>50%</td><td>‚â§50%</td><td><25%</td></tr>
            <tr><td>PaCO2</td><td><42</td><td>Normal (concerning)</td><td>Elevated</td></tr>
        </table>
        
        <div class="danger-box">
            <strong>Normal or rising PaCO2</strong> in acute asthma = impending respiratory failure. Patient is tiring and cannot maintain hyperventilation.
        </div>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Oxygen:</strong> Target SpO2 93-95%</li>
            <li><strong>SABA:</strong> Albuterol nebulizer Q20min √ó 3, then Q1-4h</li>
            <li><strong>Ipratropium:</strong> Add in severe exacerbations</li>
            <li><strong>Systemic corticosteroids:</strong> Prednisone 40-60mg daily √ó 5-7 days (or IV methylprednisolone)</li>
            <li><strong>Magnesium sulfate:</strong> 2g IV over 20 min (severe, not responding)</li>
            <li><strong>Consider:</strong> BiPAP, heliox, intubation if deteriorating</li>
        </ul>
        
        <div class="clinical-pearl">
            Discharge criteria: PEF >70% predicted, sustained on Q4h bronchodilators, SpO2 >94% on room air.
        </div>
    </div>
</div>

<!-- SECTION 3: COPD -->
<div class="section" id="copd">
    <div class="section-header">
        <h2>3. COPD <span class="badge badge-common">Very Common</span></h2>
    </div>
    <div class="section-content">
        <h3>Definition</h3>
        <ul>
            <li>Chronic airflow limitation that is NOT fully reversible</li>
            <li>FEV1/FVC <0.70 post-bronchodilator</li>
            <li>Emphysema + chronic bronchitis phenotypes</li>
        </ul>
        
        <h3>GOLD Spirometric Classification</h3>
        <table>
            <tr><th>Stage</th><th>FEV1 (% predicted)</th></tr>
            <tr><td>GOLD 1 (Mild)</td><td>‚â•80%</td></tr>
            <tr><td>GOLD 2 (Moderate)</td><td>50-79%</td></tr>
            <tr><td>GOLD 3 (Severe)</td><td>30-49%</td></tr>
            <tr><td>GOLD 4 (Very Severe)</td><td><30%</td></tr>
        </table>
        
        <h3>GOLD 2024 ABE Assessment</h3>
        <table>
            <tr><th>Group</th><th>Exacerbations</th><th>mMRC/CAT</th><th>Initial Treatment</th></tr>
            <tr><td><strong>A</strong></td><td>0-1 (no hospitalization)</td><td>mMRC 0-1 or CAT <10</td><td>Bronchodilator</td></tr>
            <tr><td><strong>B</strong></td><td>0-1 (no hospitalization)</td><td>mMRC ‚â•2 or CAT ‚â•10</td><td>LABA + LAMA</td></tr>
            <tr><td><strong>E</strong></td><td>‚â•2 moderate OR ‚â•1 hospitalized</td><td>Any</td><td>LABA + LAMA (+ ICS if eos ‚â•300)</td></tr>
        </table>
        
        <div class="guideline-box">
            <strong>GOLD 2024:</strong> ICS added to LABA/LAMA if blood eosinophils ‚â•300 cells/ŒºL and continued exacerbations. Avoid ICS if eosinophils <100.
        </div>
        
        <h3>Interventions That Improve Survival</h3>
        <div class="mnemonic-box">
            <strong>"STOP" dying from COPD:</strong><br>
            <strong>S</strong>moking cessation<br>
            <strong>T</strong>reatment with oxygen (if hypoxemic)<br>
            <strong>O</strong>peration (lung volume reduction in select patients)<br>
            <strong>P</strong>ulmonic rehab (reduces mortality in some studies)
        </div>
        
        <h3>Oxygen Therapy</h3>
        <ul>
            <li><strong>Indications:</strong> PaO2 ‚â§55 mmHg OR SpO2 ‚â§88% at rest</li>
            <li>PaO2 56-59 with cor pulmonale, polycythemia, or pulmonary HTN</li>
            <li>Use ‚â•15 hours/day for mortality benefit</li>
        </ul>
        
        <h3>Alpha-1 Antitrypsin Deficiency</h3>
        <ul>
            <li>Test ALL symptomatic patients with COPD, especially if <45 years, basilar emphysema, or family history</li>
            <li><strong>PiZZ genotype:</strong> Severe deficiency (<50 mg/dL)</li>
            <li><strong>Treatment:</strong> IV augmentation therapy if FEV1 35-65%</li>
        </ul>
    </div>
</div>

<!-- SECTION 4: COPD EXACERBATION -->
<div class="section" id="aecopd">
    <div class="section-header">
        <h2>4. COPD Exacerbation <span class="badge badge-danger">Emergency</span></h2>
    </div>
    <div class="section-content">
        <h3>Definition</h3>
        <p>Acute worsening of dyspnea, cough, and/or sputum beyond normal day-to-day variation</p>
        
        <h3>Triggers</h3>
        <ul>
            <li><strong>Infectious (70%):</strong> Viral (rhinovirus, influenza), bacterial (H. influenzae, M. catarrhalis, S. pneumoniae, P. aeruginosa in severe COPD)</li>
            <li><strong>Non-infectious:</strong> Pollution, weather, PE, CHF, non-adherence</li>
        </ul>
        
        <h3>Treatment</h3>
        <table>
            <tr><th>Intervention</th><th>Details</th></tr>
            <tr><td><strong>Bronchodilators</strong></td><td>SABA ¬± ipratropium</td></tr>
            <tr><td><strong>Systemic steroids</strong></td><td>Prednisone 40mg √ó 5 days</td></tr>
            <tr><td><strong>Antibiotics</strong></td><td>If increased sputum purulence + dyspnea or volume; or if requiring mechanical ventilation</td></tr>
            <tr><td><strong>Oxygen</strong></td><td>Target SpO2 88-92% (avoid suppressing hypoxic drive)</td></tr>
            <tr><td><strong>NIV (BiPAP)</strong></td><td>pH <7.35, PaCO2 >45; reduces intubation and mortality</td></tr>
        </table>
        
        <div class="high-yield">
            <strong>BiPAP in AECOPD:</strong> Reduces mortality, intubation, and hospital stay. Use early when pH <7.35 with hypercapnia.
        </div>
        
        <h3>Antibiotic Selection</h3>
        <table>
            <tr><th>Severity</th><th>First-Line</th><th>Alternative</th></tr>
            <tr><td>Mild-Moderate</td><td>Amoxicillin-clavulanate, doxycycline, azithromycin</td><td>Respiratory fluoroquinolone</td></tr>
            <tr><td>Severe/Pseudomonas risk</td><td>Respiratory FQ or anti-pseudomonal Œ≤-lactam</td><td>‚Äî</td></tr>
        </table>
    </div>
</div>

<!-- SECTION 5: BRONCHIECTASIS -->
<div class="section" id="bronchiectasis">
    <div class="section-header">
        <h2>5. Bronchiectasis <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Definition</h3>
        <p>Permanent airway dilation from chronic inflammation/infection</p>
        
        <h3>Etiologies</h3>
        <table>
            <tr><th>Category</th><th>Causes</th></tr>
            <tr><td><strong>Post-infectious</strong></td><td>TB, NTM, severe pneumonia (most common worldwide)</td></tr>
            <tr><td><strong>Genetic</strong></td><td>Cystic fibrosis, primary ciliary dyskinesia, alpha-1 AT</td></tr>
            <tr><td><strong>Immune</strong></td><td>CVID, HIV, hypogammaglobulinemia</td></tr>
            <tr><td><strong>Aspiration</strong></td><td>Recurrent aspiration</td></tr>
            <tr><td><strong>Autoimmune</strong></td><td>RA, Sj√∂gren's, IBD</td></tr>
            <tr><td><strong>ABPA</strong></td><td>Central bronchiectasis, Aspergillus sensitization</td></tr>
        </table>
        
        <h3>Diagnosis</h3>
        <ul>
            <li><strong>CT chest:</strong> Bronchial dilation (internal diameter > adjacent vessel = "signet ring sign")</li>
            <li>Lack of normal bronchial tapering</li>
            <li>Bronchi visible within 1 cm of pleura</li>
        </ul>
        
        <h3>Workup for Etiology</h3>
        <ul>
            <li>Immunoglobulins (IgG, IgA, IgM)</li>
            <li>Aspergillus IgE, total IgE (ABPA screen)</li>
            <li>CF sweat chloride or genetics if <40 years</li>
            <li>Sputum culture (including AFB, fungal)</li>
            <li>Consider: Ciliary biopsy, alpha-1 AT, autoimmune serologies</li>
        </ul>
        
        <h3>Management</h3>
        <ul>
            <li><strong>Airway clearance:</strong> Chest physiotherapy, oscillating devices, hypertonic saline nebulizer</li>
            <li><strong>Chronic macrolide:</strong> Azithromycin 3√ó/week if ‚â•3 exacerbations/year (reduces exacerbations)</li>
            <li><strong>Inhaled antibiotics:</strong> For chronic Pseudomonas</li>
            <li><strong>Treat underlying cause</strong></li>
        </ul>
    </div>
</div>

<!-- SECTION 6: CYSTIC FIBROSIS -->
<div class="section" id="cf">
    <div class="section-header">
        <h2>6. Cystic Fibrosis <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Genetics & Pathophysiology</h3>
        <ul>
            <li>Autosomal recessive ‚Äî CFTR gene mutation</li>
            <li>F508del most common mutation (70%)</li>
            <li>Defective chloride channel ‚Üí thick secretions</li>
        </ul>
        
        <h3>Clinical Manifestations</h3>
        <table>
            <tr><th>System</th><th>Features</th></tr>
            <tr><td><strong>Pulmonary</strong></td><td>Chronic productive cough, bronchiectasis, recurrent infections (Pseudomonas, S. aureus)</td></tr>
            <tr><td><strong>GI</strong></td><td>Pancreatic insufficiency (85%), meconium ileus, DIOS, rectal prolapse</td></tr>
            <tr><td><strong>Hepatic</strong></td><td>Biliary cirrhosis</td></tr>
            <tr><td><strong>Endocrine</strong></td><td>CF-related diabetes (CFRD)</td></tr>
            <tr><td><strong>Reproductive</strong></td><td>Male infertility (CBAVD), reduced female fertility</td></tr>
            <tr><td><strong>Other</strong></td><td>Sinusitis, nasal polyps, osteoporosis</td></tr>
        </table>
        
        <h3>Diagnosis</h3>
        <ul>
            <li><strong>Sweat chloride test:</strong> ‚â•60 mEq/L diagnostic</li>
            <li><strong>CFTR genetic testing:</strong> 2 disease-causing mutations</li>
            <li>Newborn screening (immunoreactive trypsinogen)</li>
        </ul>
        
        <h3>CFTR Modulators (Game-Changers)</h3>
        <table>
            <tr><th>Drug</th><th>Mechanism</th><th>Indication</th></tr>
            <tr><td><strong>Elexacaftor/Tezacaftor/Ivacaftor (Trikafta)</strong></td><td>Corrector + potentiator</td><td>‚â•1 F508del mutation (90% of patients)</td></tr>
            <tr><td><strong>Ivacaftor (Kalydeco)</strong></td><td>Potentiator</td><td>Gating mutations</td></tr>
        </table>
        
        <div class="high-yield">
            Trikafta has transformed CF care ‚Äî dramatically improves FEV1, reduces exacerbations, and improves quality of life. Eligible for ~90% of CF patients.
        </div>
    </div>
</div>

<!-- SECTION 7: ILD OVERVIEW -->
<div class="section" id="ild">
    <div class="section-header">
        <h2>7. Interstitial Lung Disease ‚Äî Overview <span class="badge badge-boards">Boards Favorite</span></h2>
    </div>
    <div class="section-content">
        <h3>Classification</h3>
        <table>
            <tr><th>Category</th><th>Examples</th></tr>
            <tr><td><strong>Known cause</strong></td><td>Drug-induced, CTD-ILD, hypersensitivity pneumonitis, pneumoconioses</td></tr>
            <tr><td><strong>Idiopathic interstitial pneumonias</strong></td><td>IPF, NSIP, COP, AIP, DIP, RB-ILD, LIP</td></tr>
            <tr><td><strong>Granulomatous</strong></td><td>Sarcoidosis, HP</td></tr>
            <tr><td><strong>Other</strong></td><td>LAM, pulmonary alveolar proteinosis, eosinophilic pneumonia</td></tr>
        </table>
        
        <h3>Clinical Features</h3>
        <ul>
            <li>Progressive dyspnea on exertion</li>
            <li>Dry cough</li>
            <li><strong>Exam:</strong> "Velcro" crackles (bibasilar), clubbing (IPF)</li>
        </ul>
        
        <h3>PFT Pattern</h3>
        <ul>
            <li><strong>Restrictive:</strong> ‚Üì TLC, ‚Üì FVC, FEV1/FVC normal or ‚Üë</li>
            <li><strong>‚Üì DLCO:</strong> Often reduced out of proportion</li>
        </ul>
        
        <h3>HRCT Patterns</h3>
        <table>
            <tr><th>Pattern</th><th>Features</th><th>Associations</th></tr>
            <tr><td><strong>UIP</strong></td><td>Basal, peripheral reticular + honeycombing + traction bronchiectasis</td><td>IPF, CTD-ILD, drug, asbestosis</td></tr>
            <tr><td><strong>NSIP</strong></td><td>Basal ground-glass + reticular, subpleural sparing</td><td>CTD-ILD, drug, idiopathic</td></tr>
            <tr><td><strong>OP</strong></td><td>Patchy consolidation, peribronchovascular, migratory</td><td>COP, infection, drug</td></tr>
            <tr><td><strong>HP</strong></td><td>Upper/mid zone ground-glass, centrilobular nodules, mosaic</td><td>Bird, mold exposure</td></tr>
        </table>
    </div>
</div>

<!-- SECTION 8: IPF -->
<div class="section" id="ipf">
    <div class="section-header">
        <h2>8. Idiopathic Pulmonary Fibrosis <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Definition</h3>
        <ul>
            <li>Chronic, progressive fibrosing ILD of unknown cause</li>
            <li>UIP pattern on HRCT or biopsy</li>
            <li>Exclusion of known causes</li>
        </ul>
        
        <h3>Risk Factors</h3>
        <ul>
            <li>Age >60 (rare <50)</li>
            <li>Male sex</li>
            <li>Smoking history</li>
            <li>GERD</li>
        </ul>
        
        <h3>Diagnosis</h3>
        <ul>
            <li><strong>HRCT UIP pattern:</strong> Diagnostic if definite UIP + no identifiable cause</li>
            <li><strong>UIP features:</strong> Basal/peripheral predominance, honeycombing, traction bronchiectasis, reticular abnormality, absence of inconsistent features</li>
            <li><strong>Surgical lung biopsy:</strong> If HRCT indeterminate and would change management</li>
        </ul>
        
        <div class="clinical-pearl">
            Definite UIP on HRCT in appropriate clinical context = IPF diagnosis without biopsy. "Probable UIP" may also suffice with multidisciplinary discussion.
        </div>
        
        <h3>Treatment</h3>
        <table>
            <tr><th>Drug</th><th>Mechanism</th><th>Benefit</th></tr>
            <tr><td><strong>Pirfenidone</strong></td><td>Antifibrotic (TGF-Œ≤ inhibition)</td><td>Slows FVC decline</td></tr>
            <tr><td><strong>Nintedanib</strong></td><td>Tyrosine kinase inhibitor</td><td>Slows FVC decline</td></tr>
        </table>
        
        <ul>
            <li><strong>Lung transplantation:</strong> Only curative option</li>
            <li><strong>Supplemental O2:</strong> For hypoxemia</li>
            <li><strong>Pulmonary rehabilitation</strong></li>
        </ul>
        
        <div class="danger-box">
            <strong>DO NOT use steroids or immunosuppressants in IPF</strong> ‚Äî PANTHER trial showed harm (prednisone + azathioprine + NAC increased mortality).
        </div>
        
        <h3>Prognosis</h3>
        <ul>
            <li>Median survival 3-5 years from diagnosis</li>
            <li>Acute exacerbations carry high mortality (>50%)</li>
        </ul>
    </div>
</div>

<!-- SECTION 9: HYPERSENSITIVITY PNEUMONITIS -->
<div class="section" id="hp">
    <div class="section-header">
        <h2>9. Hypersensitivity Pneumonitis <span class="badge badge-boards">Boards Favorite</span></h2>
    </div>
    <div class="section-content">
        <h3>Definition</h3>
        <p>Immune-mediated ILD from inhalation of organic antigens</p>
        
        <h3>Common Causes</h3>
        <table>
            <tr><th>Disease</th><th>Antigen</th><th>Exposure</th></tr>
            <tr><td>Bird fancier's lung</td><td>Avian proteins</td><td>Pigeons, parakeets, chickens</td></tr>
            <tr><td>Farmer's lung</td><td>Thermophilic actinomycetes</td><td>Moldy hay</td></tr>
            <tr><td>Hot tub lung</td><td>M. avium complex</td><td>Hot tubs, showers</td></tr>
            <tr><td>Humidifier lung</td><td>Various</td><td>Contaminated HVAC</td></tr>
        </table>
        
        <h3>Classification</h3>
        <table>
            <tr><th>Type</th><th>Timing</th><th>Features</th></tr>
            <tr><td><strong>Acute</strong></td><td>4-8h post-exposure</td><td>Flu-like symptoms, dyspnea, fever, cough; resolves with avoidance</td></tr>
            <tr><td><strong>Chronic (fibrotic)</strong></td><td>Insidious</td><td>Progressive dyspnea, fibrosis on CT, may be irreversible</td></tr>
        </table>
        
        <h3>Diagnosis</h3>
        <ul>
            <li><strong>History:</strong> Exposure identification is key!</li>
            <li><strong>HRCT:</strong> Upper/mid zone ground-glass, centrilobular nodules, mosaic attenuation, air trapping</li>
            <li><strong>BAL:</strong> Lymphocytosis (>30%), low CD4:CD8 ratio</li>
            <li><strong>Serum precipitins:</strong> Supportive but not diagnostic</li>
        </ul>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Antigen avoidance:</strong> Most important!</li>
            <li><strong>Corticosteroids:</strong> For acute/subacute symptomatic disease</li>
            <li><strong>Antifibrotics:</strong> Consider for progressive fibrotic HP</li>
        </ul>
        
        <div class="high-yield">
            Chronic fibrotic HP can look like IPF on CT (honeycombing, fibrosis). Key difference: HP has upper/mid distribution, air trapping, and often identifiable exposure.
        </div>
    </div>
</div>

<!-- SECTION 10: SARCOIDOSIS -->
<div class="section" id="sarcoid">
    <div class="section-header">
        <h2>10. Sarcoidosis <span class="badge badge-common">Common</span></h2>
    </div>
    <div class="section-content">
        <h3>Overview</h3>
        <ul>
            <li>Multisystem granulomatous disease of unknown cause</li>
            <li>Non-caseating granulomas</li>
            <li>Peak: 25-35 years; higher incidence in Black and Scandinavian populations</li>
        </ul>
        
        <h3>Organ Involvement</h3>
        <table>
            <tr><th>Organ</th><th>Manifestations</th></tr>
            <tr><td><strong>Lung (>90%)</strong></td><td>Bilateral hilar adenopathy, parenchymal infiltrates, fibrosis</td></tr>
            <tr><td><strong>Skin</strong></td><td>Erythema nodosum (good prognosis), lupus pernio (bad prognosis)</td></tr>
            <tr><td><strong>Eye</strong></td><td>Uveitis (anterior > posterior)</td></tr>
            <tr><td><strong>Heart</strong></td><td>AV block, arrhythmias, cardiomyopathy</td></tr>
            <tr><td><strong>Neuro</strong></td><td>CN VII palsy (most common), meningitis, mass lesions</td></tr>
            <tr><td><strong>Other</strong></td><td>Hypercalcemia, hepatosplenomegaly, arthritis</td></tr>
        </table>
        
        <h3>Chest Radiograph Staging</h3>
        <table>
            <tr><th>Stage</th><th>Findings</th><th>Spontaneous Remission</th></tr>
            <tr><td>0</td><td>Normal</td><td>‚Äî</td></tr>
            <tr><td>I</td><td>Bilateral hilar adenopathy</td><td>55-90%</td></tr>
            <tr><td>II</td><td>Adenopathy + parenchymal infiltrates</td><td>40-70%</td></tr>
            <tr><td>III</td><td>Parenchymal infiltrates only</td><td>10-20%</td></tr>
            <tr><td>IV</td><td>Fibrosis</td><td>0%</td></tr>
        </table>
        
        <h3>Diagnosis</h3>
        <ul>
            <li>Clinical + radiographic findings</li>
            <li><strong>Tissue biopsy:</strong> Non-caseating granulomas (exclude infection, malignancy)</li>
            <li><strong>ACE level:</strong> Elevated in 60% but neither sensitive nor specific</li>
        </ul>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>Observation:</strong> Many patients remit spontaneously (Stage I)</li>
            <li><strong>Corticosteroids:</strong> First-line when treatment needed</li>
            <li><strong>Steroid-sparing:</strong> Methotrexate, azathioprine, mycophenolate</li>
            <li><strong>Anti-TNF:</strong> Infliximab for refractory disease</li>
        </ul>
        
        <div class="mnemonic-box">
            <strong>L√∂fgren syndrome:</strong> Bilateral hilar adenopathy + erythema nodosum + arthralgias ¬± fever. Good prognosis, often self-limited.
        </div>
    </div>
</div>

<!-- SECTIONS 11-45 CONTINUE -->
<!-- Including: Pneumoconioses, CTD-ILD, Drug-induced ILD, Pneumonia, TB, NTM, Lung Abscess, Aspergillus, PE/VTE, Pulmonary HTN, Pleural Effusion, Pneumothorax, Lung Cancer, Solitary Pulmonary Nodule, OSA, OHS, ARDS, Mechanical Ventilation, PFTs, ABGs, and more -->

<!-- SECTION 11: PNEUMOCONIOSES -->
<div class="section" id="pneumoconioses">
    <div class="section-header">
        <h2>11. Pneumoconioses <span class="badge badge-boards">Boards Favorite</span></h2>
    </div>
    <div class="section-content">
        <table>
            <tr><th>Disease</th><th>Exposure</th><th>Imaging</th><th>Associations</th></tr>
            <tr><td><strong>Asbestosis</strong></td><td>Shipyard, insulation, construction</td><td>Lower lobe fibrosis, pleural plaques</td><td>Mesothelioma, lung cancer (synergistic with smoking)</td></tr>
            <tr><td><strong>Silicosis</strong></td><td>Mining, sandblasting, quarry</td><td>Upper lobe nodules, eggshell calcification of hilar nodes</td><td>TB risk increased</td></tr>
            <tr><td><strong>Coal worker's</strong></td><td>Coal mining</td><td>Upper lobe nodules, PMF</td><td>Caplan syndrome (RA + nodules)</td></tr>
            <tr><td><strong>Berylliosis</strong></td><td>Aerospace, electronics</td><td>Looks like sarcoidosis</td><td>BeLPT for diagnosis</td></tr>
        </table>
        
        <div class="high-yield">
            <strong>Pleural plaques</strong> = asbestos exposure marker. <strong>Eggshell calcification</strong> of hilar nodes = silicosis. Upper lobe = silicosis/coal; lower lobe = asbestosis.
        </div>
    </div>
</div>

<!-- SECTION 12: PULMONARY EMBOLISM -->
<div class="section" id="vte">
    <div class="section-header">
        <h2>12. Pulmonary Embolism <span class="badge badge-danger">Emergency</span></h2>
    </div>
    <div class="section-content">
        <h3>Clinical Presentation</h3>
        <ul>
            <li>Dyspnea (most common), pleuritic chest pain, cough, hemoptysis</li>
            <li>Tachycardia, tachypnea, hypoxemia</li>
            <li>Signs of DVT (unilateral leg swelling)</li>
        </ul>
        
        <h3>Pretest Probability ‚Äî Wells Score for PE</h3>
        <table>
            <tr><th>Criteria</th><th>Points</th></tr>
            <tr><td>Clinical signs of DVT</td><td>3</td></tr>
            <tr><td>PE most likely diagnosis</td><td>3</td></tr>
            <tr><td>Heart rate >100</td><td>1.5</td></tr>
            <tr><td>Immobilization or surgery in past 4 weeks</td><td>1.5</td></tr>
            <tr><td>Previous DVT/PE</td><td>1.5</td></tr>
            <tr><td>Hemoptysis</td><td>1</td></tr>
            <tr><td>Malignancy</td><td>1</td></tr>
        </table>
        <p><strong>Low:</strong> <2; <strong>Moderate:</strong> 2-6; <strong>High:</strong> >6</p>
        
        <h3>Diagnostic Approach</h3>
        <ul>
            <li><strong>Low pretest:</strong> D-dimer ‚Üí if negative, PE excluded</li>
            <li><strong>High pretest or positive D-dimer:</strong> CT pulmonary angiography</li>
            <li><strong>If CTPA contraindicated:</strong> V/Q scan, lower extremity ultrasound</li>
        </ul>
        
        <h3>Risk Stratification</h3>
        <table>
            <tr><th>Category</th><th>Features</th><th>Mortality</th></tr>
            <tr><td><strong>Massive (High-risk)</strong></td><td>Hemodynamic instability (SBP <90, shock)</td><td>25-50%</td></tr>
            <tr><td><strong>Submassive (Intermediate)</strong></td><td>RV dysfunction (echo/CT) or elevated troponin/BNP</td><td>3-15%</td></tr>
            <tr><td><strong>Low-risk</strong></td><td>Hemodynamically stable, no RV dysfunction</td><td><1%</td></tr>
        </table>
        
        <h3>Treatment</h3>
        <table>
            <tr><th>Severity</th><th>Treatment</th></tr>
            <tr><td><strong>Low-risk</strong></td><td>Anticoagulation (DOAC preferred), consider outpatient</td></tr>
            <tr><td><strong>Submassive</strong></td><td>Anticoagulation, close monitoring, consider escalation if deteriorating</td></tr>
            <tr><td><strong>Massive</strong></td><td>Systemic thrombolysis (tPA) or catheter-directed therapy + anticoagulation</td></tr>
        </table>
        
        <div class="guideline-box">
            <strong>Anticoagulation duration:</strong><br>
            ‚Ä¢ Provoked (surgery, immobilization): 3 months<br>
            ‚Ä¢ Unprovoked: ‚â•3 months, then reassess for indefinite<br>
            ‚Ä¢ Cancer-associated: DOAC or LMWH, continue while cancer active
        </div>
        
        <div class="danger-box">
            <strong>Thrombolysis contraindications:</strong> Recent surgery/trauma, active bleeding, hemorrhagic stroke, ischemic stroke <3 months, intracranial malignancy.
        </div>
    </div>
</div>

<!-- SECTION 13: PULMONARY HYPERTENSION -->
<div class="section" id="pah">
    <div class="section-header">
        <h2>13. Pulmonary Hypertension <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Definition (2022 ESC/ERS)</h3>
        <p><strong>mPAP >20 mmHg</strong> at rest by right heart catheterization</p>
        
        <h3>WHO Classification</h3>
        <table>
            <tr><th>Group</th><th>Category</th><th>Examples</th></tr>
            <tr><td><strong>1</strong></td><td>Pulmonary arterial hypertension (PAH)</td><td>Idiopathic, heritable, CTD, drugs, HIV, porto-pulmonary</td></tr>
            <tr><td><strong>2</strong></td><td>Left heart disease</td><td>HFrEF, HFpEF, valvular disease (MOST COMMON)</td></tr>
            <tr><td><strong>3</strong></td><td>Lung disease/hypoxia</td><td>COPD, ILD, OSA, altitude</td></tr>
            <tr><td><strong>4</strong></td><td>Chronic thromboembolic (CTEPH)</td><td>Unresolved PE</td></tr>
            <tr><td><strong>5</strong></td><td>Multifactorial</td><td>Sarcoidosis, sickle cell, metabolic</td></tr>
        </table>
        
        <h3>Hemodynamic Definitions</h3>
        <table>
            <tr><th>Type</th><th>mPAP</th><th>PAWP</th><th>PVR</th></tr>
            <tr><td><strong>Pre-capillary (Groups 1,3,4,5)</strong></td><td>>20</td><td>‚â§15</td><td>‚â•3 WU</td></tr>
            <tr><td><strong>Post-capillary (Group 2)</strong></td><td>>20</td><td>>15</td><td><3 WU</td></tr>
            <tr><td><strong>Combined</strong></td><td>>20</td><td>>15</td><td>‚â•3 WU</td></tr>
        </table>
        
        <h3>Workup</h3>
        <ul>
            <li>Echo (screen), BNP</li>
            <li>PFTs, HRCT (Group 3)</li>
            <li>V/Q scan (rule out CTEPH ‚Äî Group 4)</li>
            <li>CTD serologies, HIV, LFTs</li>
            <li><strong>Right heart catheterization:</strong> Required for diagnosis and treatment decisions</li>
        </ul>
        
        <h3>Treatment of PAH (Group 1)</h3>
        <ul>
            <li><strong>General:</strong> Diuretics, oxygen, anticoagulation (selected patients)</li>
            <li><strong>Vasodilator testing:</strong> If positive ‚Üí CCB (rare)</li>
            <li><strong>Combination therapy:</strong> ERA + PDE5i or ERA + prostacyclin analog</li>
        </ul>
        
        <table>
            <tr><th>Class</th><th>Examples</th></tr>
            <tr><td>Endothelin receptor antagonists (ERA)</td><td>Ambrisentan, bosentan, macitentan</td></tr>
            <tr><td>PDE-5 inhibitors</td><td>Sildenafil, tadalafil</td></tr>
            <tr><td>sGC stimulator</td><td>Riociguat</td></tr>
            <tr><td>Prostacyclin pathway</td><td>Epoprostenol (IV), treprostinil, selexipag</td></tr>
        </table>
        
        <div class="high-yield">
            <strong>CTEPH (Group 4)</strong> is potentially curable with pulmonary thromboendarterectomy (PTE). Always screen with V/Q scan ‚Äî CTPA may miss it.
        </div>
    </div>
</div>

<!-- SECTION 14: PLEURAL EFFUSION -->
<div class="section" id="pleural">
    <div class="section-header">
        <h2>14. Pleural Effusion <span class="badge badge-common">Common</span></h2>
    </div>
    <div class="section-content">
        <h3>Light's Criteria (Exudate if ANY)</h3>
        <div class="formula-box">
            <br>1. Pleural protein / Serum protein > 0.5<br>
            2. Pleural LDH / Serum LDH > 0.6<br>
            3. Pleural LDH > 2/3 upper limit of normal serum LDH
        </div>
        
        <h3>Transudates</h3>
        <ul>
            <li>Heart failure (most common)</li>
            <li>Cirrhosis (hepatic hydrothorax)</li>
            <li>Nephrotic syndrome</li>
            <li>Hypoalbuminemia</li>
        </ul>
        
        <h3>Exudates</h3>
        <table>
            <tr><th>Cause</th><th>Clues</th></tr>
            <tr><td><strong>Parapneumonic/empyema</strong></td><td>pH <7.2, glucose <60, positive culture/Gram stain</td></tr>
            <tr><td><strong>Malignancy</strong></td><td>Bloody, low glucose, positive cytology</td></tr>
            <tr><td><strong>TB</strong></td><td>Lymphocytic, low glucose, elevated ADA (>40)</td></tr>
            <tr><td><strong>Rheumatoid</strong></td><td>Very low glucose (<30), low pH, high LDH</td></tr>
            <tr><td><strong>Lupus</strong></td><td>ANA positive in fluid</td></tr>
            <tr><td><strong>Pancreatitis</strong></td><td>Elevated amylase (left-sided)</td></tr>
            <tr><td><strong>Esophageal rupture</strong></td><td>Very high amylase (salivary), low pH</td></tr>
            <tr><td><strong>Chylothorax</strong></td><td>Milky, triglycerides >110 mg/dL</td></tr>
        </table>
        
        <h3>When to Drain (Complicated Parapneumonic/Empyema)</h3>
        <ul>
            <li>Pus or positive Gram stain/culture</li>
            <li>pH <7.2</li>
            <li>Glucose <60 mg/dL</li>
            <li>Loculated effusion</li>
        </ul>
        
        <div class="clinical-pearl">
            If Light's criteria suggest exudate but clinical picture is transudate (e.g., diuresed CHF), check serum-pleural albumin gradient (>1.2 g/dL = transudate).
        </div>
    </div>
</div>

<!-- SECTION 15: PNEUMOTHORAX -->
<div class="section" id="ptx">
    <div class="section-header">
        <h2>15. Pneumothorax <span class="badge badge-danger">Emergency</span></h2>
    </div>
    <div class="section-content">
        <h3>Types</h3>
        <table>
            <tr><th>Type</th><th>Cause</th></tr>
            <tr><td><strong>Primary spontaneous</strong></td><td>Rupture of apical blebs; tall, thin young males, smokers</td></tr>
            <tr><td><strong>Secondary spontaneous</strong></td><td>Underlying lung disease (COPD, CF, Pneumocystis, LAM)</td></tr>
            <tr><td><strong>Traumatic</strong></td><td>Blunt/penetrating trauma, iatrogenic (central line, thoracentesis)</td></tr>
            <tr><td><strong>Tension</strong></td><td>One-way valve mechanism ‚Üí hemodynamic collapse</td></tr>
        </table>
        
        <h3>Tension Pneumothorax</h3>
        <ul>
            <li><strong>Clinical diagnosis:</strong> Hypotension, JVD, tracheal deviation, absent breath sounds</li>
            <li><strong>Treatment:</strong> Immediate needle decompression (2nd ICS, MCL) ‚Üí chest tube</li>
        </ul>
        
        <div class="danger-box">
            <strong>Tension pneumothorax is a clinical diagnosis.</strong> Do NOT wait for imaging. Needle decompression, then chest tube.
        </div>
        
        <h3>Management</h3>
        <table>
            <tr><th>Scenario</th><th>Treatment</th></tr>
            <tr><td>Small primary, stable</td><td>Observation, supplemental O2 (accelerates reabsorption)</td></tr>
            <tr><td>Large primary or symptomatic</td><td>Aspiration or small-bore chest tube</td></tr>
            <tr><td>Secondary pneumothorax</td><td>Chest tube (higher complication risk)</td></tr>
            <tr><td>Tension</td><td>Needle decompression ‚Üí chest tube</td></tr>
            <tr><td>Recurrent</td><td>Pleurodesis or VATS</td></tr>
        </table>
    </div>
</div>

<!-- SECTION 16-30: More critical topics -->

<div class="section" id="ards">
    <div class="section-header">
        <h2>16. ARDS <span class="badge badge-danger">Emergency</span></h2>
    </div>
    <div class="section-content">
        <h3>Berlin Definition (2012)</h3>
        <table>
            <tr><th>Criteria</th><th>Requirement</th></tr>
            <tr><td><strong>Timing</strong></td><td>Within 1 week of insult or new/worsening symptoms</td></tr>
            <tr><td><strong>Imaging</strong></td><td>Bilateral opacities not fully explained by effusion, collapse, nodules</td></tr>
            <tr><td><strong>Origin</strong></td><td>Not fully explained by cardiac failure/fluid overload</td></tr>
            <tr><td><strong>Oxygenation</strong></td><td>PaO2/FiO2 ‚â§300 with PEEP ‚â•5 cm H2O</td></tr>
        </table>
        
        <h3>Severity</h3>
        <table>
            <tr><th>Severity</th><th>P/F Ratio</th><th>Mortality</th></tr>
            <tr><td>Mild</td><td>200-300</td><td>27%</td></tr>
            <tr><td>Moderate</td><td>100-200</td><td>32%</td></tr>
            <tr><td>Severe</td><td><100</td><td>45%</td></tr>
        </table>
        
        <h3>Evidence-Based Management</h3>
        <table>
            <tr><th>Intervention</th><th>Evidence</th></tr>
            <tr><td><strong>Low tidal volume (6 mL/kg IBW)</strong></td><td>ARDSNet ‚Äî reduces mortality</td></tr>
            <tr><td><strong>Plateau pressure <30 cm H2O</strong></td><td>Lung-protective ventilation</td></tr>
            <tr><td><strong>Conservative fluid management</strong></td><td>FACTT ‚Äî improves oxygenation, ventilator-free days</td></tr>
            <tr><td><strong>Prone positioning (if P/F <150)</strong></td><td>PROSEVA ‚Äî reduces mortality in severe ARDS</td></tr>
            <tr><td><strong>Neuromuscular blockade (early severe)</strong></td><td>ACURASYS ‚Äî may reduce mortality</td></tr>
            <tr><td><strong>ECMO (refractory)</strong></td><td>EOLIA ‚Äî consider in severe refractory ARDS</td></tr>
        </table>
        
        <div class="high-yield">
            <strong>Lung-protective ventilation:</strong> Vt 6 mL/kg IBW, plateau <30, permissive hypercapnia acceptable. Proved mortality benefit.
        </div>
    </div>
</div>

<div class="section" id="mechanical-vent">
    <div class="section-header">
        <h2>17. Mechanical Ventilation Basics <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Modes</h3>
        <table>
            <tr><th>Mode</th><th>Description</th><th>Use</th></tr>
            <tr><td><strong>Volume Control (AC/VC)</strong></td><td>Set Vt, rate; variable pressure</td><td>Most common initial mode</td></tr>
            <tr><td><strong>Pressure Control (PC)</strong></td><td>Set pressure, rate; variable Vt</td><td>High airway pressures, comfort</td></tr>
            <tr><td><strong>Pressure Support (PS)</strong></td><td>Patient-triggered, set pressure</td><td>Weaning, spontaneous trials</td></tr>
            <tr><td><strong>SIMV</strong></td><td>Guaranteed rate + spontaneous breaths</td><td>Weaning (less used now)</td></tr>
        </table>
        
        <h3>Initial Settings</h3>
        <ul>
            <li><strong>Tidal volume:</strong> 6-8 mL/kg IBW (6 in ARDS)</li>
            <li><strong>Rate:</strong> 12-16 (adjust for pH/PaCO2)</li>
            <li><strong>FiO2:</strong> Start 100%, wean to SpO2 92-96%</li>
            <li><strong>PEEP:</strong> 5-8 cm H2O (higher in ARDS)</li>
        </ul>
        
        <h3>Troubleshooting High Airway Pressures</h3>
        <table>
            <tr><th>Finding</th><th>Cause</th><th>Examples</th></tr>
            <tr><td>‚Üë Peak AND ‚Üë Plateau</td><td>Low compliance</td><td>ARDS, pulmonary edema, atelectasis, pneumothorax</td></tr>
            <tr><td>‚Üë Peak, normal Plateau</td><td>High resistance</td><td>Bronchospasm, mucus plug, kinked tube</td></tr>
        </table>
        
        <h3>Liberation from Ventilation</h3>
        <ul>
            <li><strong>Spontaneous Breathing Trial (SBT):</strong> PS 5-8/PEEP 5 or T-piece √ó 30-120 min</li>
            <li><strong>RSBI:</strong> RR/Vt (L) ‚Äî <105 predicts success</li>
            <li><strong>Passed SBT:</strong> Proceed to extubation if cough, mental status, secretions adequate</li>
        </ul>
    </div>
</div>

<div class="section" id="sleep">
    <div class="section-header">
        <h2>18. Obstructive Sleep Apnea <span class="badge badge-common">Very Common</span></h2>
    </div>
    <div class="section-content">
        <h3>Definition</h3>
        <ul>
            <li><strong>AHI ‚â•5</strong> with symptoms OR <strong>AHI ‚â•15</strong> regardless of symptoms</li>
            <li>AHI = apneas + hypopneas per hour of sleep</li>
        </ul>
        
        <h3>Severity</h3>
        <table>
            <tr><th>Severity</th><th>AHI</th></tr>
            <tr><td>Mild</td><td>5-14</td></tr>
            <tr><td>Moderate</td><td>15-29</td></tr>
            <tr><td>Severe</td><td>‚â•30</td></tr>
        </table>
        
        <h3>Clinical Features</h3>
        <ul>
            <li>Snoring, witnessed apneas</li>
            <li>Excessive daytime sleepiness (Epworth Sleepiness Scale)</li>
            <li>Morning headaches, nocturia</li>
            <li>Associated: HTN (especially resistant), A-fib, stroke, metabolic syndrome</li>
        </ul>
        
        <h3>Diagnosis</h3>
        <ul>
            <li><strong>Polysomnography (PSG):</strong> Gold standard</li>
            <li><strong>Home sleep apnea testing (HSAT):</strong> For high pretest probability, no significant comorbidities</li>
        </ul>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>CPAP:</strong> First-line for moderate-severe OSA</li>
            <li><strong>Weight loss:</strong> Significant improvement</li>
            <li><strong>Oral appliance:</strong> Mild-moderate OSA or CPAP intolerant</li>
            <li><strong>Surgery:</strong> Selected cases (UPPP, maxillomandibular advancement)</li>
            <li><strong>Hypoglossal nerve stimulation:</strong> CPAP-intolerant with moderate-severe OSA</li>
        </ul>
        
        <div class="clinical-pearl">
            All patients with resistant hypertension should be screened for OSA. Treatment of OSA modestly reduces BP.
        </div>
    </div>
</div>

<div class="section" id="ohs">
    <div class="section-header">
        <h2>19. Obesity Hypoventilation Syndrome</h2>
    </div>
    <div class="section-content">
        <h3>Definition</h3>
        <ul>
            <li>BMI ‚â•30 kg/m¬≤</li>
            <li>Awake daytime hypercapnia (PaCO2 >45 mmHg)</li>
            <li>Exclusion of other causes of hypoventilation</li>
            <li>90% have concurrent OSA</li>
        </ul>
        
        <h3>Treatment</h3>
        <ul>
            <li><strong>CPAP:</strong> If concurrent OSA without severe hypercapnia</li>
            <li><strong>BiPAP:</strong> If significant hypercapnia or CPAP failure</li>
            <li><strong>Weight loss:</strong> Most effective long-term</li>
        </ul>
    </div>
</div>

<div class="section" id="lung-cancer">
    <div class="section-header">
        <h2>20. Lung Cancer <span class="badge badge-common">Common</span></h2>
    </div>
    <div class="section-content">
        <h3>Types</h3>
        <table>
            <tr><th>Type</th><th>%</th><th>Location</th><th>Features</th></tr>
            <tr><td><strong>Adenocarcinoma</strong></td><td>40%</td><td>Peripheral</td><td>Most common; non-smokers; EGFR, ALK, ROS1 mutations</td></tr>
            <tr><td><strong>Squamous cell</strong></td><td>25%</td><td>Central</td><td>Cavitation; hypercalcemia (PTHrP)</td></tr>
            <tr><td><strong>Small cell (SCLC)</strong></td><td>15%</td><td>Central</td><td>Aggressive; paraneoplastic syndromes; SIADH, Cushing's, Lambert-Eaton</td></tr>
            <tr><td><strong>Large cell</strong></td><td>10%</td><td>Peripheral</td><td>Poorly differentiated</td></tr>
        </table>
        
        <h3>Screening (USPSTF 2021)</h3>
        <ul>
            <li>Age 50-80 years</li>
            <li>‚â•20 pack-year smoking history</li>
            <li>Current smoker or quit within past 15 years</li>
            <li><strong>Annual low-dose CT</strong></li>
        </ul>
        
        <h3>Staging (NSCLC)</h3>
        <ul>
            <li><strong>Stage I-II:</strong> Surgical resection (curative intent)</li>
            <li><strong>Stage III:</strong> Chemoradiation ¬± surgery</li>
            <li><strong>Stage IV:</strong> Systemic therapy (targeted therapy if driver mutation, immunotherapy, chemo)</li>
        </ul>
        
        <h3>SCLC</h3>
        <ul>
            <li><strong>Limited stage:</strong> Confined to one hemithorax/radiation field ‚Üí chemoradiation, prophylactic cranial irradiation</li>
            <li><strong>Extensive stage:</strong> Chemo + immunotherapy (atezolizumab)</li>
        </ul>
        
        <h3>Paraneoplastic Syndromes</h3>
        <table>
            <tr><th>Syndrome</th><th>Tumor Type</th><th>Mechanism</th></tr>
            <tr><td>Hypercalcemia</td><td>Squamous cell</td><td>PTHrP</td></tr>
            <tr><td>SIADH</td><td>SCLC</td><td>ADH secretion</td></tr>
            <tr><td>Cushing's</td><td>SCLC</td><td>Ectopic ACTH</td></tr>
            <tr><td>Lambert-Eaton</td><td>SCLC</td><td>Anti-VGCC antibodies</td></tr>
            <tr><td>Hypertrophic osteoarthropathy</td><td>NSCLC</td><td>Clubbing, periostitis</td></tr>
        </table>
    </div>
</div>

<div class="section" id="spn">
    <div class="section-header">
        <h2>21. Solitary Pulmonary Nodule <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Definition</h3>
        <p>Round lesion ‚â§3 cm, surrounded by lung parenchyma, no adenopathy/atelectasis</p>
        
        <h3>Benign vs Malignant Features</h3>
        <table>
            <tr><th>Benign</th><th>Malignant</th></tr>
            <tr><td>Stable ‚â•2 years</td><td>New or growing</td></tr>
            <tr><td><6 mm, smooth borders</td><td>>8 mm, spiculated</td></tr>
            <tr><td>Central/popcorn calcification</td><td>Eccentric calcification</td></tr>
            <tr><td>Fat density (hamartoma)</td><td>Part-solid (ground-glass component)</td></tr>
        </table>
        
        <h3>Management (Fleischner Society)</h3>
        <ul>
            <li><strong><6 mm solid:</strong> No routine follow-up (low risk); optional 12-month CT (high risk)</li>
            <li><strong>6-8 mm solid:</strong> CT at 6-12 months; consider 18-24 month follow-up</li>
            <li><strong>>8 mm solid:</strong> CT at 3 months, PET, and/or biopsy based on probability</li>
            <li><strong>Ground-glass (pure):</strong> CT at 6-12 months; if persistent, annual follow-up √ó 5 years</li>
            <li><strong>Part-solid:</strong> Higher malignancy risk ‚Äî CT at 3-6 months, then annual √ó 5 years</li>
        </ul>
        
        <div class="clinical-pearl">
            Ground-glass nodules (especially part-solid) have higher malignancy risk than solid nodules of the same size. Follow longer.
        </div>
    </div>
</div>

<div class="section" id="pfts">
    <div class="section-header">
        <h2>22. Pulmonary Function Tests <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Spirometry Patterns</h3>
        <table>
            <tr><th>Pattern</th><th>FEV1</th><th>FVC</th><th>FEV1/FVC</th><th>Examples</th></tr>
            <tr><td><strong>Obstructive</strong></td><td>‚Üì‚Üì</td><td>‚Üì or N</td><td><strong><0.70</strong></td><td>Asthma, COPD, bronchiectasis</td></tr>
            <tr><td><strong>Restrictive</strong></td><td>‚Üì</td><td>‚Üì‚Üì</td><td><strong>N or ‚Üë</strong></td><td>ILD, chest wall disease, neuromuscular</td></tr>
            <tr><td><strong>Mixed</strong></td><td>‚Üì‚Üì</td><td>‚Üì‚Üì</td><td><0.70</td><td>Combined disease</td></tr>
        </table>
        
        <h3>Lung Volumes</h3>
        <table>
            <tr><th>Finding</th><th>Obstructive</th><th>Restrictive</th></tr>
            <tr><td>TLC</td><td>‚Üë (air trapping)</td><td>‚Üì</td></tr>
            <tr><td>RV</td><td>‚Üë‚Üë</td><td>‚Üì</td></tr>
            <tr><td>RV/TLC</td><td>‚Üë</td><td>N or ‚Üì</td></tr>
        </table>
        
        <h3>DLCO Interpretation</h3>
        <table>
            <tr><th>DLCO</th><th>Causes</th></tr>
            <tr><td><strong>Decreased</strong></td><td>ILD, emphysema, pulmonary vascular disease (PE, PAH), anemia</td></tr>
            <tr><td><strong>Increased</strong></td><td>Polycythemia, pulmonary hemorrhage, asthma, left-to-right shunt, obesity</td></tr>
        </table>
        
        <div class="mnemonic-box">
            <strong>Low DLCO:</strong> "PEACE" ‚Äî Pulmonary vascular, Emphysema, Anemia, Collagen vascular/ILD, Emboli
        </div>
        
        <h3>Bronchodilator Response</h3>
        <ul>
            <li><strong>Positive:</strong> ‚â•12% AND ‚â•200 mL increase in FEV1 or FVC</li>
            <li>Suggests reversible airflow obstruction (asthma)</li>
        </ul>
    </div>
</div>

<div class="section" id="abg">
    <div class="section-header">
        <h2>23. ABG Interpretation <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Systematic Approach</h3>
        <ol>
            <li><strong>Acidemia or alkalemia?</strong> pH <7.35 = acidemia; pH >7.45 = alkalemia</li>
            <li><strong>Primary disorder?</strong> Check PaCO2 (respiratory) and HCO3 (metabolic)</li>
            <li><strong>Compensation appropriate?</strong> Calculate expected compensation</li>
            <li><strong>If metabolic acidosis:</strong> Calculate anion gap</li>
            <li><strong>If elevated AG:</strong> Calculate delta-delta ratio</li>
        </ol>
        
        <h3>Compensation Formulas</h3>
        <div class="formula-box">
            <br><strong>Metabolic acidosis:</strong> Expected PaCO2 = 1.5 √ó HCO3 + 8 (¬±2) [Winter's]<br>
            <strong>Metabolic alkalosis:</strong> Expected PaCO2 = 0.7 √ó HCO3 + 21 (¬±2)<br>
            <strong>Respiratory acidosis (acute):</strong> HCO3 ‚Üë 1 per 10 mmHg ‚Üë PaCO2<br>
            <strong>Respiratory acidosis (chronic):</strong> HCO3 ‚Üë 3.5 per 10 mmHg ‚Üë PaCO2<br>
            <strong>Respiratory alkalosis (acute):</strong> HCO3 ‚Üì 2 per 10 mmHg ‚Üì PaCO2<br>
            <strong>Respiratory alkalosis (chronic):</strong> HCO3 ‚Üì 5 per 10 mmHg ‚Üì PaCO2
        </div>
        
        <h3>Anion Gap</h3>
        <div class="formula-box">
            <br>AG = Na - (Cl + HCO3)<br>
            Normal = 8-12 mEq/L
        </div>
        
        <h3>Delta-Delta Ratio</h3>
        <div class="formula-box">
            <br>ŒîAG / ŒîHCO3 = (AG - 12) / (24 - HCO3)<br>
            <1 = concurrent non-AG metabolic acidosis<br>
            1-2 = pure AG metabolic acidosis<br>
            >2 = concurrent metabolic alkalosis
        </div>
    </div>
</div>

<!-- Continue with remaining sections -->

<div class="section" id="pneumonia">
    <div class="section-header">
        <h2>24. Community-Acquired Pneumonia <span class="badge badge-common">Very Common</span></h2>
    </div>
    <div class="section-content">
        <h3>Common Pathogens</h3>
        <ul>
            <li><strong>Typical:</strong> S. pneumoniae (most common), H. influenzae, M. catarrhalis</li>
            <li><strong>Atypical:</strong> Mycoplasma, Chlamydophila, Legionella</li>
            <li><strong>Viral:</strong> Influenza, RSV, SARS-CoV-2</li>
        </ul>
        
        <h3>Severity Assessment ‚Äî CURB-65</h3>
        <table>
            <tr><th>Criteria</th><th>Points</th></tr>
            <tr><td>Confusion</td><td>1</td></tr>
            <tr><td>Urea >7 mmol/L (BUN >20)</td><td>1</td></tr>
            <tr><td>Respiratory rate ‚â•30</td><td>1</td></tr>
            <tr><td>Blood pressure (SBP <90 or DBP ‚â§60)</td><td>1</td></tr>
            <tr><td>Age ‚â•65</td><td>1</td></tr>
        </table>
        <p>0-1: Outpatient; 2: Consider admission; ‚â•3: ICU consideration</p>
        
        <h3>Treatment (ATS/IDSA 2019)</h3>
        <table>
            <tr><th>Setting</th><th>Regimen</th></tr>
            <tr><td><strong>Outpatient, healthy</strong></td><td>Amoxicillin OR doxycycline OR macrolide (if local resistance <25%)</td></tr>
            <tr><td><strong>Outpatient, comorbidities</strong></td><td>Amoxicillin-clavulanate + macrolide OR respiratory FQ</td></tr>
            <tr><td><strong>Inpatient, non-severe</strong></td><td>Œ≤-lactam + macrolide OR respiratory FQ</td></tr>
            <tr><td><strong>Inpatient, severe/ICU</strong></td><td>Œ≤-lactam + macrolide (or FQ); add vanc/linezolid if MRSA risk</td></tr>
        </table>
    </div>
</div>

<div class="section" id="tb">
    <div class="section-header">
        <h2>25. Tuberculosis <span class="badge badge-boards">High-Yield</span></h2>
    </div>
    <div class="section-content">
        <h3>Latent vs Active TB</h3>
        <table>
            <tr><th>Feature</th><th>Latent TB (LTBI)</th><th>Active TB</th></tr>
            <tr><td>Symptoms</td><td>None</td><td>Cough, fever, night sweats, weight loss</td></tr>
            <tr><td>CXR</td><td>Normal</td><td>Abnormal (cavities, infiltrates)</td></tr>
            <tr><td>Infectious</td><td>No</td><td>Yes</td></tr>
            <tr><td>TST/IGRA</td><td>Positive</td><td>Usually positive</td></tr>
        </table>
        
        <h3>Diagnosis of Active TB</h3>
        <ul>
            <li>Sputum AFB smear √ó 3</li>
            <li>Sputum culture (gold standard)</li>
            <li>Nucleic acid amplification test (NAAT)</li>
            <li>CXR: Upper lobe infiltrates, cavitation, miliary pattern</li>
        </ul>
        
        <h3>Treatment of Active TB</h3>
        <div class="mnemonic-box">
            <strong>"RIPE":</strong> Rifampin, Isoniazid, Pyrazinamide, Ethambutol<br>
            2 months intensive (RIPE) ‚Üí 4 months continuation (RI)
        </div>
        
        <h3>LTBI Treatment</h3>
        <ul>
            <li><strong>3HP:</strong> INH + rifapentine weekly √ó 12 weeks (preferred)</li>
            <li><strong>4R:</strong> Rifampin daily √ó 4 months</li>
            <li><strong>9H:</strong> INH daily √ó 9 months</li>
        </ul>
        
        <h3>Drug Toxicities</h3>
        <table>
            <tr><th>Drug</th><th>Toxicity</th></tr>
            <tr><td>Isoniazid</td><td>Hepatitis, peripheral neuropathy (give B6), drug-induced lupus</td></tr>
            <tr><td>Rifampin</td><td>Hepatitis, orange secretions, drug interactions (CYP450 inducer)</td></tr>
            <tr><td>Pyrazinamide</td><td>Hepatitis, hyperuricemia</td></tr>
            <tr><td>Ethambutol</td><td>Optic neuritis (check visual acuity)</td></tr>
        </table>
    </div>
</div>

<!-- Final sections: Board Pearls -->
<div class="section" id="pearls">
    <div class="section-header">
        <h2>45. High-Yield Board Pearls</h2>
    </div>
    <div class="section-content">
        <h3>Obstructive Disease</h3>
        <ul>
            <li>üíé FEV1/FVC <0.70 = obstruction; REVERSIBILITY (‚â•12% + 200mL) suggests asthma</li>
            <li>üíé Normal or rising PaCO2 in acute asthma = impending respiratory failure</li>
            <li>üíé GOLD 2024: ICS in COPD if eosinophils ‚â•300; avoid if <100</li>
            <li>üíé Only smoking cessation and O2 (if hypoxemic) proven to improve COPD survival</li>
        </ul>
        
        <h3>Interstitial Lung Disease</h3>
        <ul>
            <li>üíé UIP pattern = honeycombing, basal/peripheral, traction bronchiectasis</li>
            <li>üíé NO steroids in IPF ‚Äî PANTHER trial showed harm</li>
            <li>üíé Chronic HP can mimic IPF; look for upper lobe involvement, exposure history</li>
            <li>üíé Pleural plaques = asbestos; eggshell nodes = silicosis</li>
        </ul>
        
        <h3>Pulmonary Vascular</h3>
        <ul>
            <li>üíé V/Q scan is screening test for CTEPH (CTPA may miss it)</li>
            <li>üíé Right heart cath required for PH diagnosis and treatment decisions</li>
            <li>üíé Massive PE = hemodynamic instability ‚Üí thrombolysis</li>
        </ul>
        
        <h3>Critical Care</h3>
        <ul>
            <li>üíé ARDS: Low Vt (6 mL/kg IBW), plateau <30, prone if P/F <150</li>
            <li>üíé BiPAP in AECOPD reduces intubation and mortality</li>
            <li>üíé Target SpO2 88-92% in COPD (avoid suppressing hypoxic drive)</li>
        </ul>
        
        <h3>Pleural Disease</h3>
        <ul>
            <li>üíé Light's criteria: any 1 of 3 = exudate</li>
            <li>üíé pH <7.2 in parapneumonic effusion = drain</li>
            <li>üíé Tension pneumothorax = clinical diagnosis, immediate decompression</li>
        </ul>
        
        <h3>Lung Cancer</h3>
        <ul>
            <li>üíé Screening: Age 50-80, ‚â•20 pack-years, current or quit <15 years ‚Üí annual LDCT</li>
            <li>üíé SCLC: Central, aggressive, paraneoplastic (SIADH, Cushing's, Lambert-Eaton)</li>
            <li>üíé Squamous: Central, cavitates, hypercalcemia (PTHrP)</li>
        </ul>
    </div>
</div>

<button class="back-to-top" id="backToTop" onclick="scrollToTop()">‚Üë</button>

<footer>
    <h3 style="margin: 0 0 10px;">ü´Å ABIM Pulmonology Study Guide</h3>
    <p style="opacity: 0.9; font-size: 0.9rem;">ATS ‚Ä¢ GOLD ‚Ä¢ CHEST Guidelines</p>
    <div style="margin-top: 20px;">
        <a href="index.html">üìö Clinical Suite</a>
        <a href="im_guide.html">ü©∫ IM Guide</a>
        <a href="id_study_guide.html">ü¶† ID Guide</a>
        <a href="cardio_study_guide.html">‚ù§Ô∏è Cardio</a>
        <a href="endocrinology_study_guide.html">üî¨ Endo</a>
    </div>
</footer>

<script>
    const searchBox = document.getElementById('searchBox');
    searchBox.addEventListener('input', function() {
        const query = this.value.toLowerCase();
        document.querySelectorAll('.section').forEach(section => {
            section.style.display = (query === '' || section.textContent.toLowerCase().includes(query)) ? 'block' : 'none';
        });
    });
    
    const backToTopBtn = document.getElementById('backToTop');
    window.addEventListener('scroll', () => backToTopBtn.classList.toggle('show', window.pageYOffset > 400));
    function scrollToTop() { window.scrollTo({ top: 0, behavior: 'smooth' }); }
    
    document.querySelectorAll('.section-header').forEach(header => {
        header.addEventListener('click', () => header.parentElement.classList.toggle('collapsed'));
    });
</script>

</body>
</html>
